Medtronic plc (MDT) Q1 FY2027 8-K Filings and Company Events

Filings that contain financial statements

• 8-K, accession 0001628280-26-059697 (filed September 1, 2026), Exhibit 99.1 furnishes Medtronic's full press-release financial statements (condensed consolidated statements of income, GAAP-to-non-GAAP reconciliations, and condensed consolidated statements of cash flows) for the first quarter of fiscal year 2027, the quarter ended July 31, 2026.
• 8-K, accession 0001628280-26-040034 (filed June 3, 2026), Exhibit 99.1 furnishes full fourth-quarter and full-year fiscal 2026 results (income statement, reconciliations, cash flow statement) for the quarter and year ended April 24, 2026.
• 8-K, accession 0001628280-26-008300 (filed February 17, 2026), Exhibit 99.1 furnishes third-quarter fiscal 2026 results.
• 8-K, accession 0001628280-25-052771 (filed November 18, 2025), Exhibit 99.1 furnishes second-quarter fiscal 2026 results.
• 8-K, accession 0001613103-25-000141 (filed August 19, 2025), Exhibit 99.1 furnishes first-quarter fiscal 2026 results.
• 8-K, accession 0001613103-25-000078 (filed May 21, 2025), Exhibit 99.1 furnishes fourth-quarter and full-year fiscal 2025 results.
• 10-Q, accession 0001628280-26-060473 (filed September 3, 2026, period ended July 31, 2026), carries the full unaudited condensed consolidated financial statements for Q1 FY2027, including the acquisition and MiniMed-separation disclosures summarized below.
• 10-K, accession 0001628280-26-044354 (filed June 18, 2026, period ended April 24, 2026), carries the full audited consolidated financial statements for fiscal year 2026.

Earnings and guidance

• September 1, 2026 (Q1 FY2027 results, accession 0001628280-26-059697): Revenue of $9.8 billion, up 13.7% as reported and organic. GAAP diluted EPS of $1.14; non-GAAP diluted EPS of $1.45. Medtronic raised its fiscal 2027 organic revenue growth guidance by 50 basis points to 7.25%–7.75% and raised non-GAAP diluted EPS guidance to $5.94–$6.00 (from $5.90–$6.00). Organic growth was broad-based: Cardiovascular up 18.9% (Cardiac Ablation Solutions up 88%), Neuroscience up 9.3%, Medical Surgical up 10.2%, and Diabetes up 14.9%. Results included a roughly $570 million organic-growth benefit from an extra fiscal week in the quarter.
• June 3, 2026 (Q4 and full-year FY2026 results, accession 0001628280-26-040034): Q4 revenue of $9.8 billion, up 9.9% as reported and 6.6% organic. Full fiscal 2026 revenue of $36.4 billion, up 8.4% as reported and 5.8% organic, described as the company's highest annual revenue growth in 10 years. FY2026 GAAP diluted EPS of $3.73 and non-GAAP diluted EPS of $5.53. FY2026 cash from operations of $7.3 billion and free cash flow of $5.4 billion; the company returned $4.2 billion to shareholders during the year. Medtronic guided FY2027 organic revenue growth to 6.75%–7.25% and non-GAAP diluted EPS to $5.90–$6.00 (guidance later raised in the September 2026 release above).
• March 24, 2026 (guidance update, accession 0001613103-26-000005): Ahead of Q4 FY2026 results, Medtronic disclosed that a $157 million one-time charge tied to a Blackstone Life Sciences royalty/milestone arrangement on the MiniMed Flex insulin pump, plus dilution from the March 9, 2026 MiniMed initial public offering, would reduce fiscal 2026 non-GAAP EPS guidance to $5.50–$5.54 from the prior $5.62–$5.66. Fiscal 2027 EPS guidance of high-single-digit growth was left unchanged. The filing also disclosed FDA clearance of the MiniMed Flex insulin pump, months ahead of schedule.
• February 17, 2026 (Q3 FY2026 results, accession 0001628280-26-008300): Third-quarter fiscal 2026 results furnished via press release.
• November 18, 2025 (Q2 FY2026 results, accession 0001628280-25-052771): Second-quarter fiscal 2026 results furnished via press release.
• August 19, 2025 (Q1 FY2026 results, accession 0001613103-25-000141): First-quarter fiscal 2026 results furnished via press release.
• May 21, 2025 (Q4/FY2025 results, accession 0001613103-25-000078): Fourth-quarter and full fiscal 2025 results furnished via press release.

Dividend

• June 3, 2026 (accession 0001628280-26-040034): The board approved a dividend increase for the first quarter of fiscal 2027, raising the quarterly dividend to $0.72 per ordinary share (an annualized $2.88), marking the 49th consecutive year of dividend increases. Payable July 17, 2026, to shareholders of record June 26, 2026.

Diabetes business separation

• May 21, 2025 (accession 0001613103-25-000078, Exhibit 99.2): Medtronic announced its intent to separate its Diabetes business into a new standalone, publicly traded company, targeting completion within 18 months through a series of capital markets transactions (an IPO followed by a split-off was the preferred structure at the time). The Diabetes business represented approximately 8% of fiscal 2025 revenue and 4% of segment operating profit.
• Subsequent developments (per the fiscal 2026 10-K, accession 0001628280-26-044354, and the Q1 FY2027 10-Q, accession 0001628280-26-060473): The new entity was named MiniMed Group, Inc. On March 9, 2026, MiniMed completed an initial public offering of 28,000,000 shares of common stock at $20.00 per share, generating net proceeds of $538 million, and began trading on the Nasdaq Global Select Market under the symbol "MMED." Medtronic retained a controlling financial interest following the IPO, so MiniMed's results continued to be consolidated into Medtronic's financial statements. As of the Q1 FY2027 10-Q (filed September 3, 2026), Medtronic stated it plans to complete the full separation of the Diabetes business within the current fiscal year; the September 1, 2026 earnings release described the remaining separation as expected to occur through a spin-off, split-off, offering, or combination, with a split-off the company's then-current preferred structure and no final decision yet reached.
• In December 2025, Medtronic's board approved restructuring actions tied to the MiniMed separation, incurring associated restructuring charges disclosed in both the 10-K and the Q1 FY2027 10-Q.

Acquisitions

• CathWorks Ltd., closed. On April 20, 2026, Medtronic acquired all remaining outstanding shares of CathWorks Ltd., a privately held medical device company, expanding its Coronary & Peripheral Vascular business within Cardiovascular. Total consideration transferred was $525 million, including $115 million of contingent consideration (per the fiscal 2026 10-K, accession 0001628280-26-044354). This transaction closed before Medtronic's fiscal year-end and was not the subject of a standalone 8-K in the reviewed filings; it was first disclosed in the June 3, 2026 Q4 earnings release as a completed "tuck-in" deal.
• Scientia Vascular, closed. On June 12, 2026, Medtronic closed its acquisition of all outstanding shares of Scientia Vascular, a privately held company, expanding the Specialty Therapies division within Neuroscience with neurovascular access products. Per the Q1 FY2027 10-Q (accession 0001628280-26-060473), total purchase price was $681 million, including $123 million of contingent consideration. This acquisition was announced as intended in the June 3, 2026 earnings release and confirmed closed in the September 1, 2026 earnings release and the Q1 FY2027 10-Q; it was not the subject of a standalone 8-K.
• SPR Therapeutics, Inc., closed. On July 16, 2026, Medtronic closed its acquisition of all outstanding equity of SPR Therapeutics, Inc., a privately held medical technology company, expanding the Neuromodulation division within Neuroscience with temporary peripheral nerve stimulation technology. Per the Q1 FY2027 10-Q, total consideration was $654 million. This deal was likewise first disclosed as intended (May 2026, referenced in the June 3, 2026 release) and confirmed closed in the September 1, 2026 earnings release and the Q1 FY2027 10-Q; no standalone 8-K covers it.
• Pi-Cardia, minority investment. The September 1, 2026 earnings release (accession 0001628280-26-059697) disclosed a strategic investment in Pi-Cardia, a leaflet-modification technology company; no financial terms were disclosed.
• Pulnovo Medical, minority investment. The June 3, 2026 earnings release disclosed a Q4 FY2026 investment in Pulnovo Medical within Cardiovascular; no financial terms were disclosed.
• Cornerstone Robotics, strategic partnership and investment. On September 1, 2026, Medtronic announced a strategic partnership with Cornerstone Robotics, a surgical robotics company, comprising an investment in Cornerstone plus rights to distribute Cornerstone's Sentire surgical system in select markets outside the U.S. where the system is market approved. Per the Q1 FY2027 10-Q (accession 0001628280-26-060473, Note 19, Subsequent Events) and the September 1, 2026 earnings release (accession 0001628280-26-059697), Medtronic paid approximately $700 million in cash for the investment in the second quarter of fiscal 2027, recorded primarily as an increase in other assets. No equity percentage or valuation was disclosed.
• Anteris, M&A transaction. The Q3 FY2026 earnings release (accession 0001628280-26-008300) described Anteris, in Structural Heart, alongside CathWorks as one of "two key transactions in the quarter" under Medtronic's M&A strategy; no financial terms were disclosed.

Note: none of the acquisitions above (CathWorks, Scientia Vascular, SPR Therapeutics) were the subject of their own Item 1.01/2.01 Form 8-K in the filings reviewed; their closings are documented in Medtronic's earnings press releases and confirmed in the notes to the fiscal 2026 Form 10-K and the Q1 fiscal 2027 Form 10-Q.

Debt financing

• September 15–29, 2025 (accessions 0001193125-25-205061 and 0001193125-25-221819): Medtronic, Inc. priced and then issued €750 million of 2.950% Senior Notes due 2030 and €750 million of 4.200% Senior Notes due 2045 under its existing shelf registration, guaranteed by Medtronic plc and Medtronic Global Holdings S.C.A. Net proceeds of approximately €1.49 billion were used to repay two separate Medtronic Luxco note series: €500 million of 2.625% Senior Notes due 2025, redeemed at par on September 29, 2025 for $587 million, and €1.0 billion of 0.000% Senior Notes due 2025, repaid for $1.2 billion in October 2025 (per the fiscal 2026 10-K, accession 0001628280-26-044354). This is separate from the €1.0 billion of Senior Notes Medtronic repaid at maturity for $1.2 billion in July 2025.
• August 2026 (10-Q, accession 0001628280-26-060473, Note 19, Subsequent Events): Subsequent to quarter-end, Medtronic entered into a cross-currency swap derivative contract with a notional amount of $1.0 billion, designated as a net investment hedge of Chinese Renminbi-denominated exposures from its investments in certain CNY functional-currency subsidiaries.

Cybersecurity incident

• April 24, 2026 (accession 0001628280-26-027272): Medtronic disclosed that an unauthorized third party had accessed data in certain corporate information technology systems. The company said it had not identified any impact to its products, patient safety, customer connections, manufacturing and distribution operations, or financial reporting systems, and did not expect a material impact on its business or financial results. The company engaged external cybersecurity experts and activated incident response protocols.

Governance and management changes

• March 12/17, 2025 (accession 0001613103-25-000034): Jennifer M. Kirk, Global Controller and Principal Accounting Officer, resigned effective May 2, 2025, to become CEO of a private company. Denise L. Blomquist, previously Assistant Global Controller, was appointed to succeed her effective March 17, 2025.
• May 21, 2025 (accession 0001613103-25-000078): Sean Salmon departed as EVP and President, Cardiovascular Portfolio; Skip Kiil assumed the role effective May 21, 2025.
• June 18, 2025 (accession 0001613103-25-000094): The board expanded from 10 to 11 members and appointed Dr. Joon Lee, CEO of Emory Healthcare, as an independent director.
• August 18, 2025 (accession 0001613103-25-000141): The board expanded from 11 to 13 members and appointed John Groetelaars and William Jellison as new directors, effective August 19, 2025.
• October 16, 2025 (accession 0001628280-25-045695): At Medtronic's Annual General Meeting, shareholders elected all twelve director nominees, ratified PricewaterhouseCoopers LLP as independent auditor, approved advisory "say-on-pay," and approved amendments to the company's Memorandum and Articles of Association (Irish law provisions on distributable reserves and advance notice requirements), which became effective the same day.
• November 1, 2025 (accession 0001628280-25-048375): Gregory L. Smith, EVP, Enterprise Operations, notified the company of his retirement effective December 2, 2025, to join a private-equity-held organization.
• May 18, 2026 (accession 0001628280-26-035959): Brett Wall departed as EVP and President, Neuroscience Portfolio; Dr. Kweli Thompson, previously SVP and President, Cardiac Rhythm Management, assumed the role effective June 1, 2026.

Other items not reflected in current SEC filings

The events reviewed run through September 1, 2026. No 8-K or periodic filing in this window discloses completion of the Diabetes business's final separation from Medtronic (spin-off/split-off); as of the most recent 10-Q, that separation remained in progress, with MiniMed still consolidated into Medtronic's financial statements.